SEC ownership of Wave Life Sciences Ltd.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001631574.

Comparable stake leader

RA CAPITAL MANAGEMENT, L.P.

Disclosed value leader

GSK plc

Comparable rows

50/50

Latest evidence

15 Apr 2026

Top shareholders Insider holders Latest transactions
Public ticker
WVE on Nasdaq
Parsed ownership sources
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
RA CAPITAL MANAGEMENT, L.P.
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
RA CAPITAL MANAGEMENT, L.P.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
15 Apr 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001631574
Issuer location
Singapore, Singapore

Ownership snapshot

Top shareholders of Wave Life Sciences Ltd. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
GSK plc
Comparable rows
50/50
Latest evidence
15 Apr 2026
13D/G 3/4/5 13F Lead comparable stake: 17% 13D/G row: RA CAPITAL MANAGEMENT, L.P. Showing 1-8 of 50 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 17%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership Top 5
RA CAPITAL MANAGEMENT, L.P. 17%
BlackRock, Inc. 6.1%
MAVERICK CAPITAL LTD 5.4%
FMR LLC 2.8%
Adage Capital Management, L.P. 0.53%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
13D/G 3/4/5 13F
Director, 10%+ Owner · Company
13D/G 3/4/5 13F
17%
$248,138,341
34,225,506 shares
 $0 15 Apr 2026
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
6.1%
from 13D/G
$102,351,241
14,117,412 shares
 — 31 Mar 2026
MAVERICK CAPITAL LTD
13F 13D/G
Company
13F 13D/G
5.4%
from 13D/G
$73,670,143
10,161,399 shares
 — 31 Mar 2026
FMR LLC
13F 13D/G
Company
13F 13D/G
2.8%
from 13D/G
$37,647,520
5,192,761 shares
 — 31 Mar 2026
Adage Capital Management, L.P.
13D/G
13D/G
0.53%
$7,180,000
1,000,000 shares
 -$63,083,918 31 Mar 2026
Peter Kolchinsky
3/4/5
Director, 10%+ Owner
3/4/5
14%
$175,340,782
26,975,505 shares
 +$54,624,378 26 Mar 2026
RA Capital Healthcare Fund LP
3/4/5
Director, 10%+ Owner
3/4/5
14%
$175,340,782
26,975,505 shares
 +$54,624,378 26 Mar 2026
Rajeev M. Shah
3/4/5
Director, 10%+ Owner
3/4/5
14%
$175,340,782
26,975,505 shares
 +$54,624,378 26 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$227,760,920.

Buys
$246,434,199
Insiders: 5
Sells
$18,673,280
Insiders: 11
Net
+$227,760,920
Shares: +35,198,256
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 36,560,984 Shares: 1,362,728
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 35,089,984 0 $218,497,512 $0 +$218,497,512
3-6 0 61,748 $0 $907,810 -$907,810
6-9 1,471,000 1,036,960 $27,936,688 $15,138,725 +$12,797,962
9-12 0 264,020 $0 $2,626,744 -$2,626,744

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to Wave Life Sciences Ltd.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
GSK plc
Net 12M change
+$227,760,919
Latest report
09 Apr 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
GSK plc 10%+ Owner $346,668,129 +$27,930,000 +8.8% Filing P/S 11 Dec 2025
RA Capital Healthcare Fund LP Director, 10%+ Owner $175,340,782 +$54,624,378 +45% Filing P/S 26 Mar 2026
Peter Kolchinsky Director, 10%+ Owner $175,340,782 +$54,624,378 +45% Filing P/S 26 Mar 2026
RA CAPITAL MANAGEMENT, L.P. Director, 10%+ Owner $175,340,782 +$54,631,065 +45% Filing P/S 26 Mar 2026
Rajeev M. Shah Director, 10%+ Owner $175,340,782 +$54,624,378 +45% Filing P/S 26 Mar 2026
Ken Takanashi Director $163,715,967 -$42,630 -0.03% Mixed 23 Mar 2026
Chandra Vargeese Chief Technology Officer, Head of Platform Discovery Sciences $5,490,908 -$43,417 -0.78% Filing P/S 05 Feb 2026
Gregory L. Verdine Director $3,866,798 -$369,461 -8.7% Filing P/S 08 Dec 2025
Paul Bolno President and CEO, Director $3,705,744 -$2,335,766 -39% Filing P/S 05 Feb 2026
Kyle Moran Chief Financial Officer $1,807,478 -$4,152,238 -70% Filing P/S 05 Feb 2026
Chris Francis SVP, Corporate Development, Head of Emerging Areas $928,005 -$7,102,264 -88% Filing P/S 26 Feb 2026
Erik Ingelsson Chief Scientific Officer $637,022 Median 09 Apr 2026
Heidi L. Wagner Director $629,020 -$189,000 -23% Filing P/S 08 Dec 2025
Mark Corrigan Director $405,282 -$217,297 -35% Filing P/S 08 Dec 2025
Christopher I. Wright Chief Medical Officer $330,785 Median 09 Apr 2026
Aik Na Tan Director $323,850 -$2,027,270 -86% Filing P/S 08 Dec 2025
Henry Christian O Director $228,854 -$1,454,516 -86% Filing P/S 08 Dec 2025
Adrian Rawcliffe Director $190,500 -$739,421 -80% Filing P/S 08 Dec 2025
Michael A. Panzara Chief Medical Officer, Head of Therapeutics Discovery and Development Mixed 25 Jul 2022

Recent insider transactions for Wave Life Sciences Ltd.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
RA CAPITAL MANAGEMENT, L.P. WVE Ordinary Shares Purchase 3.73% $6,312,092 $6.50 971,091 26,975,505 30 Mar 2026 See footnotes
RA CAPITAL MANAGEMENT, L.P. WVE Ordinary Shares Purchase 3.73% $6,312,092 $6.50 971,091 26,975,505 30 Mar 2026 See footnotes
Ra Capital Management, L.P. WVE Ordinary Shares Purchase 3.73% $6,312,092 $6.50 971,091 26,975,505 30 Mar 2026 See footnotes
Ra Capital Management, L.P. WVE Ordinary Shares Purchase 3.73% $6,312,092 $6.50 971,091 26,975,505 30 Mar 2026 See footnotes
RA CAPITAL MANAGEMENT, L.P. WVE Ordinary Shares Purchase 10.6% $16,046,856 $6.43 2,495,623 26,004,414 27 Mar 2026 See footnotes
RA CAPITAL MANAGEMENT, L.P. WVE Ordinary Shares Purchase 10.6% $16,046,856 $6.43 2,495,623 26,004,414 27 Mar 2026 See footnotes
Ra Capital Management, L.P. WVE Ordinary Shares Purchase 10.6% $16,046,856 $6.43 2,495,623 26,004,414 27 Mar 2026 See footnotes
Ra Capital Management, L.P. WVE Ordinary Shares Purchase 10.6% $16,046,856 $6.43 2,495,623 26,004,414 27 Mar 2026 See footnotes
RA CAPITAL MANAGEMENT, L.P. WVE Ordinary Shares Purchase 29.2% $32,265,431 $6.08 5,305,782 23,508,791 26 Mar 2026 See footnotes
RA CAPITAL MANAGEMENT, L.P. WVE Ordinary Shares Purchase 29.2% $32,265,431 $6.08 5,305,782 23,508,791 26 Mar 2026 See footnotes
Ra Capital Management, L.P. WVE Ordinary Shares Purchase 29.2% $32,265,431 $6.08 5,305,782 23,508,791 26 Mar 2026 See footnotes
Ra Capital Management, L.P. WVE Ordinary Shares Purchase 29.2% $32,265,431 $6.08 5,305,782 23,508,791 26 Mar 2026 See footnotes
Ken Takanashi WVE Ordinary Shares Conversion of derivative security 68.4% 3,901,348 9,606,408 23 Mar 2026 See Footnote
Ken Takanashi WVE Series A Preferred Shares Conversion of derivative security -100% -3,901,348 0 23 Mar 2026 See Footnote
Chris Francis WVE Ordinary Shares Sale -34.9% $499,593 $15.05 -33,194 61,867 26 Feb 2026 Direct
Chris Francis WVE Ordinary Shares Options Exercise 71.3% 33,194 79,767 26 Feb 2026 Direct
Chris Francis WVE Share Option (right to buy) Options Exercise -35.2% -33,194 61,175 26 Feb 2026 Direct
Kyle Moran WVE Ordinary Shares Sale -2.6% $48,259 $13.45 -3,588 134,385 09 Feb 2026 Direct
Paul Bolno WVE Ordinary Shares Sale -3.66% $140,956 $13.45 -10,480 275,520 09 Feb 2026 Direct
Chris Francis WVE Ordinary Shares Sale -2.95% $25,326 $13.45 -1,883 61,867 09 Feb 2026 Direct
Chandra Vargeese WVE Ordinary Shares Sale -0.78% $43,417 $13.45 -3,228 408,246 09 Feb 2026 Direct
Kyle Moran WVE Ordinary Shares Award 49.4% 45,625 137,973 05 Feb 2026 Direct
Kyle Moran WVE Share Option (right to buy) Award 273,750 273,750 05 Feb 2026 Direct
Paul Bolno WVE Ordinary Shares Award 136.4% 165,000 286,000 05 Feb 2026 Direct
Paul Bolno WVE Share Option (right to buy) Award 1,000,000 1,000,000 05 Feb 2026 Direct
Chris Francis WVE Ordinary Shares Award 155% 38,750 63,750 05 Feb 2026 Direct
Chris Francis WVE Share Option (right to buy) Award 232,500 232,500 05 Feb 2026 Direct
Chandra Vargeese WVE Ordinary Shares Award 12.5% 45,625 411,474 05 Feb 2026 Direct
Chandra Vargeese WVE Share Option (right to buy) Award 273,750 273,750 05 Feb 2026 Direct
Chris Francis WVE Ordinary Shares Sale -27.3% $150,260 $16.03 -9,375 25,000 02 Jan 2026 Direct
Chris Francis WVE Ordinary Shares Options Exercise 37.5% 9,375 34,375 02 Jan 2026 Direct
Chris Francis WVE Share Option (right to buy) Options Exercise -100% -9,375 0 02 Jan 2026 Direct
GSK plc WVE Ordinary Shares Purchase 8.76% $27,930,000 $19.00 1,470,000 18,245,691 11 Dec 2025 By Corporation
Kyle Moran WVE Ordinary Shares Sale -35.9% $1,001,979 $20.03 -50,036 89,218 09 Dec 2025 Direct
Kyle Moran WVE Ordinary Shares Options Exercise 161.6% 86,000 139,218 09 Dec 2025 Direct
Kyle Moran WVE Share Option (right to buy) Award -100% -86,000 0 09 Dec 2025 Direct
Heidi L. Wagner WVE Ordinary Shares Sale -23.8% $189,000 $13.50 -14,000 44,930 08 Dec 2025 Direct
Heidi L. Wagner WVE Ordinary Shares Options Exercise 36.9% 14,000 51,930 08 Dec 2025 Direct
Heidi L. Wagner WVE Share Option (right to buy) Options Exercise -66.7% -14,000 7,000 08 Dec 2025 Direct
Aik Na Tan WVE Ordinary Shares Options Exercise 119,230 70,400 08 Dec 2025 Direct
Aik Na Tan WVE Ordinary Shares Sale -84.1% $1,823,158 $13.58 -134,218 25,400 08 Dec 2025 Direct
Aik Na Tan WVE Share Option (right to buy) Options Exercise -100% -119,230 0 08 Dec 2025 Direct
Chris Francis WVE Ordinary Shares Sale -94.6% $6,427,085 $14.57 -441,031 25,000 08 Dec 2025 Direct
Chris Francis WVE Ordinary Shares Options Exercise 441,031 147,349 08 Dec 2025 Direct
Chris Francis WVE Share Option (right to buy) Options Exercise -100% -441,031 0 08 Dec 2025 Direct
Kyle Moran WVE Ordinary Shares Sale -70.2% $3,102,000 $14.77 -210,000 89,218 08 Dec 2025 Direct
Kyle Moran WVE Ordinary Shares Options Exercise 210,000 189,218 08 Dec 2025 Direct
Kyle Moran WVE Share Option (right to buy) Award -100% -210,000 0 08 Dec 2025 Direct
Gregory L. Verdine WVE Ordinary Shares Sale -6.77% $269,461 $13.47 -20,000 275,217 08 Dec 2025 Direct
Adrian Rawcliffe WVE Ordinary Shares Sale -76.8% $630,000 $15.00 -42,000 12,700 08 Dec 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .